Key result
ERS 2021 highlights outline advances in PE risk stratification and targeted group 3 PH therapies.
Why the study?
To summarise the latest research and address knowledge gaps presented at the virtual 2021 ERS International Congress in pulmonary vascular disease.
This conference review synthesizes emerging evidence from the 2021 ERS International Congress on pulmonary embolism management, pulmonary hypertension classification debates, Group 3 PH phenotyping and therapy, portopulmonary hypertension, and cardiac MRI monitoring.
This article aims to summarise the latest research presented at the virtual 2021 European Respiratory Society (ERS) International Congress in the field of pulmonary vascular disease. In light of the current guidelines and proceedings, knowledge gaps are addressed and the newest findings of the various forms of pulmonary hypertension as well as key points on pulmonary embolism are discussed. Despite the comprehensive coverage of the guidelines for pulmonary embolism at previous conferences, discussions about controversies in the diagnosis and treatment of this condition in specific cases were debated and are addressed in the first section of this article. We then report on an interesting pro-con debate about the current classification of pulmonary hypertension. We further report on presentations on Group 3 pulmonary hypertension, with research exploring pathogenesis, phenotyping, diagnosis and treatment; important contributions on the diagnosis of post-capillary pulmonary hypertension are also included. Finally, we summarise the latest evidence presented on pulmonary vascular disease and COVID-19 and a statement on the new imaging guidelines for pulmonary vascular disease from the Fleischner Society.
No takes yet. Share an insight, caveat, or question.
Lichtblau et al. (2022) conducted a review in Pulmonary vascular disease (pulmonary embolism and pulmonary hypertension). Highlights from the 2021 ERS International Congress summarize recent advances in pulmonary embolism risk stratification, pulmonary hypertension phenotyping, and targeted therapies for group 3 PH.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: